Vimarsana
Biggest News Aggregation in the World

Page 4 - Primary Endpoint News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Primary Endpoint. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Primary Endpoint Today - Breaking & Trending Today

© 2023 Tonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P04 88 September 25 , 2023 (Doc 1321 ) - Form 8-K -September 25, 2023 at 04:40 pm EDT - Vimarsana News

© 2023 Tonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P04 88 September 25 , 2023 (Doc 1321 ) - Form 8-K -September 25, 2023 at 04:40 pm EDT

T ianeptine - tianeptine 1 Stablon. Summary of product characteristics. Les Laboratoires Servier Industrie ; 2014. 2 PubChem. Accessed November 10, 2022....

25% of Patients Achieve Endoscopic Remission in Phase 2a EMERALD-1 Trial for MORF-057 - Vimarsana News

25% of Patients Achieve Endoscopic Remission in Phase 2a EMERALD-1 Trial for MORF-057

Data from the phase 2a trial showed 25.7% of patients with UC demonstrated endoscopic improvement and 45.7% achieved clinical response after week 12.

Invivyd, Inc. (NASDAQ:IVVD) Q2 2023 Earnings Call Transcript - Vimarsana News

Invivyd, Inc. (NASDAQ:IVVD) Q2 2023 Earnings Call Transcript

Invivyd, Inc. (NASDAQ:IVVD) Q2 2023 Earnings Call Transcript August 12, 2023 Operator: Welcome to the Invivyd Second Quarter 2023 Business and Financial Results Update Call. I will now turn the call over to Gabriella Linville-Engler, Director of External Communications. Gabriella Linville-Engler: Thank you for joining us today. Before we get started, I want to tend […]

Source: yahoo.com
UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2023 Earnings Call Transcript - Vimarsana News

UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2023 Earnings Call Transcript

UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2023 Earnings Call Transcript August 10, 2023 UroGen Pharma Ltd. beats earnings expectations. Reported EPS is $-1.03, expectations were $-1.13. Operator: Good morning, ladies and gentlemen. Thank you for standing by. And welcome to the UroGen Pharma’s Second Quarter 2023 Earnings Call. Please be advised that today’s conference is being […]

Source: yahoo.com
BioXcel Therapeutics : Other Information - Vimarsana News

BioXcel Therapeutics : Other Information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securit...